RxDoctor Payments Data

James Connors, MD

MOHS-Micrographic Surgery · St Petersburg, FLNPI 1548255250

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Genentech USA, Inc. accounts for 61.9% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2019 at $9,392 and has fallen 88.0% since, to $1,127 in 2025.

$14,596in general payments, 2019–2025

Across 317 payments — averaging $46.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$9K
  • Novartis$1K
  • AbbVie$747
  • Sun Pharmaceutical Industries Inc.$688
  • Amgen$584
  • Regeneron Healthcare Solutions, Inc.$450
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$7,80053%
  • Travel & lodging$5344%
  • Food & beverage$6,24543%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,596 in reported general payments places this provider in the 85th percentile of 141 mohs-micrographic surgery providers in Florida.

See all mohs-micrographic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$810,942
Medicare patients
898
Services billed
4,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mupirocin12$74
Cephalexin12$39
Lorazepam17$17

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →